Clinical trials: Myelo Dysplastic Syndrome
Hematologic Malignancy
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
- Trial name
- NCT02352558
- Testing
- BBI608, Dexamethasone, Bortezomib
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sumitomo Pharma America, Inc.
Myelo Dysplastic Syndrome
What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes
to investigate prognostic significance of many factors in MDS including HALP score ( haemoglobin level, albumin level, lymphocyte, platelets), monocytopenia, hyperfibrinogenemia and AST/ALT ratio in patients with MDS at Assiut…
- Trial name
- NCT07210034
- Volunteers
- 100 people
- Sponsor
- Assiut University
Allogeneic Stem Cell Transplant, Acute Graft Versus Host Disease
Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections
This study evaluates the the pharmacokinetics of posaconazole (new solid oral and IV) given as prophylaxis to patients who are at risk for developing fungal infections after receiving conditioning therapy (except strictly…
- Conditions
- Allogeneic Stem Cell Transplant, Acute Graft Versus Host Disease, Acute Myeloid Leucaemia, Myelo Dysplastic Syndrome
- Trial name
- PIRAÑA (NCT02805946)
- Testing
- posaconazole
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 21 people
- Sponsor
- Radboud University Medical Center
VEXAS Syndome, Myelo Dysplastic Syndrome
Momelotinib in VEXAS Syndrome
Multicenter, phase II trial with safety run-in to evaluate the efficacy and safety of momelotinib in patients with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome with or without associated…
- Trial name
- NCT07098936
- Testing
- Momelotinib treatment
- Where
- 11 sites in France
- Volunteers
- 57 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Acute Graft Versus Host Disease Grade II-IV, Allogeneic Stem Cell Transplant
Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease
The primary objective of this trial is as follows: To determine the pharmacokinetics of micafungin given twice weekly in patients at risk for developing an invasive fungal disease (patients who are being treated for acute or…
- Conditions
- Acute Graft Versus Host Disease Grade II-IV, Allogeneic Stem Cell Transplant, Acute Myeloid Leucaemia, Myelo Dysplastic Syndrome
- Trial name
- MATADOR (NCT02172768)
- Testing
- alternate dosing, daily dosing, micafungin
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center